Solid dosage form rapidly disintegrating Lyophilized comprising an effective amount of a Thrombin receptor antagonist; and used to treat a patient who is at risk of coNtraer Acute Coronary Syndrome.

摘要

Disclosed is a lyophilized rapidly disintegrating solid dosage form, one embodiment of which comprises a thrombin receptor antagonist such as, or a pharmaceutically acceptable salt or hydrate thereof, a polymer such as gelatin, and a matrix forming agent such as mannitol. Systems for effectively buffering the pre-lyophilized suspension are taught, along with methods of treating patients at risk for acute coronary syndrome by administering such a rapidly disintegrating solid dosage form.